Chris Moriarty

Chris Moriarty is the CEO of Affinity Biomarker Labs, a company specializing in biomarker testing and laboratory services.12 Based in London, United Kingdom, Moriarty has extensive experience in the life sciences industry.

Professional Background

Prior to his role at Affinity Biomarker Labs, Chris Moriarty held a position at Fusion Antibodies, demonstrating his expertise in the biotechnology sector.3 His leadership at Affinity Biomarker Labs focuses on providing direct-to-patient testing and laboratory services for consumer healthcare companies.1

Education and Connections

Moriarty received his education from Queen's University Belfast.2 On LinkedIn, he maintains a network of over 500 connections, indicating his strong professional relationships within the industry.2

Role at Affinity Biomarker Labs

As CEO, Chris Moriarty leads Affinity Biomarker Labs in offering innovative solutions for blood testing and analysis. The company has been involved in advancing telehealth services, particularly during the COVID-19 pandemic.1 Under his leadership, Affinity Biomarker Labs has embraced new technologies to improve patient experience and safety in blood collection processes.1

Industry Involvement

Moriarty has been active in promoting advancements in biomarker testing and laboratory services. He has spoken about the importance of support and advice for companies looking to innovate in the healthcare sector.4 His expertise extends to areas such as direct-to-patient testing and the implementation of new blood collection technologies like the TAP II device developed by Seventh Sense Biosystems.1